Chargement en cours...
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
With an explosion of available treatments for metastatic renal cell carcinoma (mRCC) in recent years, it is important to recognize that approved targeted therapies fall broadly into only two mechanistic categories. The first category, vascular endothelial growth factor (VEGF)-directed therapies, inc...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3253822/ https://ncbi.nlm.nih.gov/pubmed/21484496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-011-0172-y |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|